Pre-Seed, Seed, Series A
$500K – $15.0M
$3.8B
10+ companies
11 partners
Investment Thesis
Third Rock focuses exclusively on life sciences companies with transformative therapeutic potential, particularly in oncology and precision medicine.
Meet the Team
Christoph Westphal
Founding Partner
Industry Focus
Invests In
Portfolio Companies (10)
Other
Allogene Therapeutics
Neon Therapeutics
Aqvesme™
"Discovered via firm_website (high confidence)"
AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia.
Syremis Therapeutics
"Discovered via firm_website (high confidence)"
Syremis is developing novel medicines to make a profound impact on the treatment of mental health.
INLEXZO™
"Discovered via firm_website (high confidence)"
INLEXZO™ (gemcitabine intravesical system) an original asset from Taris Bio, receives FDA approval.
Azalea Therapeutics
"Discovered via firm_website (high confidence)"
Azalea is enabling precision genome engineering directly inside the body, with an initial focus on creating cancer immunotherapies in vivo.
Element Science
"Discovered via firm_website (high confidence)"
Element Science receives FDA approval for the revolutionary Jewel® Patch Wearable Cardioverter Defibrillator.
Merida Biosciences
"Discovered via firm_website (high confidence)"
Merida is advancing a precision immunology approach for antibody-driven diseases that selectively and durably eliminate their pathogenic drivers.
RHYTHM METABOLIC, INC. (RYTM) (CIK 0001649904)
"Discovered via sec_edgar_form_d (high confidence)"
SEC Form D filing mentioning Third Rock Ventures
RHYTHM PHARMACEUTICALS, INC. (RYTM) (CIK 0001649904)
"Discovered via sec_edgar_form_d (high confidence)"
SEC Form D filing mentioning Third Rock Ventures
Browse More Investors
Frequently Asked Questions
See if Third Rock Ventures is a match for your startup
Upload your pitch deck to see how well you match with Third Rock Ventures and 200+ other VC firms.